State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Blood Cancer J. 2013 Aug 16;3(8):e133. doi: 10.1038/bcj.2013.31.
Minimal residual disease (MRD) is of the most important factor for predicting prognosis and guiding treatment of acute lymphoblastic leukemia (ALL). In this study, we investigated the prognostic significance of leukemia-associated immunophenotypes (LAIPs) as assessment of index of MRD in 125 adult B-lineage ALL (B-ALL) patients by eight-color flow cytometry. The LAIPs could be identified in 96% and 81.6% of patients with the sensitivity of 10(-4) and 10(-5), respectively. MRD-negative status could clearly predict a favorable 2-year relapse-free survival (RFS) and overall survival (OS) at the end of induction of complete remission and one cycle of consolidation treatment. Moreover, we identified a group of cases with MRD of 0.001% to <0.01%, which showed significantly higher 2-year relapse rate than those with undetectable one. In multivariate analysis, MRD status was associated with RFS or OS independently. Furthermore, MRD assessed by LAIPs and RQ-PCR assay for patients with BCR-ABL fusion gene yielded concordant results in 89.7% of cases. In conclusion, MRD evaluated by eight-color flow cytometry could provide an important tool to assess treatment response and prognosis precisely in adult B-ALL.
微小残留病(MRD)是预测急性淋巴细胞白血病(ALL)预后和指导治疗的最重要因素之一。本研究通过八色流式细胞术检测 125 例成人 B 细胞系 ALL(B-ALL)患者的白血病相关免疫表型(LAIPs),作为 MRD 评估指标,探讨其预后意义。LAIPs 可在 96%和 81.6%的患者中被识别,其灵敏度分别为 10(-4)和 10(-5)。诱导完全缓解和一个周期巩固治疗结束时的 MRD 阴性状态可明确预测 2 年无复发生存(RFS)和总生存(OS)。此外,我们还发现了一组 MRD 为 0.001%至<0.01%的病例,其 2 年复发率明显高于无法检测到的病例。多因素分析显示,MRD 状态与 RFS 或 OS 独立相关。此外,LAIPs 和 RQ-PCR 检测 BCR-ABL 融合基因的患者的 MRD 结果在 89.7%的病例中具有一致性。总之,八色流式细胞术评估的 MRD 可提供一种重要的工具,以精确评估成人 B-ALL 的治疗反应和预后。